CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nano Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nano Holdings Inc
Ohnoya Kyobashi Bldg., 1-4-10, Kyobashi
Phone: +81 364324791p:+81 364324791 MINATO-KU, TKY  105-6226  Japan Ticker: 45714571
Business Summary
Nano Holdings Inc is a Japan-based company mainly engaged in the micellar nanoparticle technology to develop innovative pharmaceuticals, focusing on anticancer drugs that encapsulate small molecule drugs within nanoparticles. The Company operates through a single segment encompassing the research and development, manufacturing, and sales of pharmaceuticals and related services. The Company conducts non-clinical and early-stage clinical trials, then licenses the resulting development candidate assets to pharmaceutical companies, thereby developing an RNA drug discovery business that efficiently brings RNA medicines to the market. In promoting RNA drug discovery, the Company leverages its experience in drug delivery system anticancer drug development and manufacturing, nucleic acid drug research and development, and a variety of DDS selection options based on this experience, creating and licensing assets that enable rapid progress in pharmaceutical development.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20253/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Representative Director AtsushiMatsumura 62 6/27/2025 3/21/2012
President, Chief Executive Officer, President of Subsidiary, Representative Director ShiroAkinaga 66 10/1/2023 6/1/2020
Chief Financial Officer, Executive Officer KojiFujimoto 51 6/27/2024 6/1/2020
10 additional Officers and Directors records available in full report.

Business Names
Business Name
4571
NanoCarrier Co., Ltd.

General Information
Number of Employees: 20 (As of 3/31/2025)
Outstanding Shares: 72,629,329 (As of 11/28/2025)
Shareholders: 32,107
Stock Exchange: TYO
Fax Number: +81 364324794


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 12, 2025